Does Cosentyx Cause Crohn's Disease?
No, Cosentyx (secukinumab) does not cause Crohn's disease. Clinical trials and post-marketing data show it can trigger new-onset or exacerbate existing inflammatory bowel disease (IBD), including Crohn's, in a small subset of patients—typically less than 1%—but this is a rare adverse reaction, not causation in the general sense.[1][2]
Why Does This Risk Exist with Cosentyx?
Cosentyx is an IL-17A inhibitor approved for psoriasis, psoriatic arthritis, ankylosing spondylitis, and other autoimmune conditions. IL-17 plays a role in gut inflammation, and blocking it can disrupt immune balance in the intestines, potentially worsening IBD in susceptible people. The label warns of this based on trials where 0.1-1% of patients developed IBD symptoms, often within months of starting treatment.[1][3]
Who Gets Affected and How Common Is It?
Risk is higher in patients with a personal or family history of IBD. In pooled trial data:
- New-onset Crohn's: 6 cases out of 6,132 patients (0.1%).
- Exacerbations: More frequent in those with prior IBD.
Symptoms like diarrhea, abdominal pain, or blood in stool led to discontinuation in affected cases. Real-world reports via FDA FAERS database note similar low rates, with most resolving after stopping the drug.[2][4]
What Should Patients Watch For?
Monitor for IBD signs early: persistent diarrhea, severe cramps, weight loss, or bloody stools. The prescribing information recommends screening at-risk patients and stopping Cosentyx if IBD develops. No routine gut screening is mandated for all users.[1]
How Does This Compare to Other Biologics?
| Drug | IBD Risk Profile |
|------|------------------|
| Cosentyx (IL-17 inhibitor) | Can worsen Crohn's; avoid in known IBD. |
| Stelara (IL-12/23 inhibitor) | Generally gut-protective; used to treat Crohn's. |
| Humira (TNF inhibitor) | Risk of new-onset IBD (rare); treats Crohn's. |
| Skyrizi (IL-23 inhibitor) | Low IBD risk; approved for Crohn's. |
IL-17 blockers like Cosentyx carry higher IBD warnings than IL-23 or TNF options.[3][5]
What Do Guidelines Say?
Dermatology and rheumatology societies advise against Cosentyx in active or history of IBD. If symptoms emerge, switch to alternatives like ustekinumab (Stelara).[6]
[1]: Cosentyx Prescribing Information (Novartis)
[2]: FDA Adverse Event Reporting System (FAERS) Public Dashboard
[3]: EMA Cosentyx Summary of Product Characteristics
[4]: PubMed: Secukinumab and IBD Risk (2018 Review)
[5]: Skyrizi Prescribing Information (AbbVie)
[6]: AAD Guidelines on Biologics in Psoriasis (2021)